Sanuwave Health (SNWV)
NASDAQ:SNWV
Want to see SNWV full AI Analyst Report?
SNWV Stock Chart & Stats
$31.30
$1.30(5.42%)
At close: 4:00 PM EST
$31.30
$1.30(5.42%)
Day’s Range― - ―
52-Week Range$15.36 - $46.59
Previous CloseN/A
Volume17.14K
Average Volume (3M)78.76K
Market Cap
$133.81M
Enterprise Value$144.82M
Total Cash (Recent Filing)$11.96M
Total Debt (Recent Filing)$22.97M
Price to Earnings (P/E)10.5
Beta1.14
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.26
Shares Outstanding8,594,209
10 Day Avg. Volume75,518
30 Day Avg. Volume78,757
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)157.84
Price to Sales (P/S)5.80
P/FCF Ratio132.13
Enterprise Value/Market Cap1.08
Enterprise Value/Revenue3.29
Enterprise Value/Gross Profit4.38
Enterprise Value/Ebitda23.25
Forecast
1Y Price Target
$51.00Price Target Upside62.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.39
Revenue Forecast (FY)$51.77M
Bulls Say, Bears Say
Bulls Say
Revenue & System PlacementsSustained top-line growth and a material increase in system placements indicate expanding commercial traction. Higher unit placements expand the installed base, drive recurring consumable sales and service opportunities, and create a multi-quarter tailwind to revenue and customer relationships.
High Gross Margins & Consumables MixVery strong gross margins, driven by consumables pricing and lower system costs, point to durable unit economics. A consumables-heavy mix supports recurring revenue with higher incremental margins, aiding cash-generation and the ability to scale without proportionate COGS growth.
Debt Reduction & Improved LiquidityMaterial deleveraging and refinancing lowered interest burden and financial volatility. Reduced debt and $12M cash provide more runway to execute channel shifts, invest in qualifying manufacturing molds, and absorb industry shocks, improving strategic optionality over months.
Bears Say
Thin Equity & Limited Capital CushionPersistently thin shareholders' equity leaves little buffer against earnings volatility or further write‑downs. High leverage relative to equity constrains the company’s financial flexibility, raises refinancing and covenant risk, and limits ability to fund growth without external capital.
CMS Reimbursement DisruptionA structural cut to reimbursement and tougher audit policies materially weakens provider economics for adjacent wound-care treatments. This reduces demand durability, has already driven customer churn and system removals, and may permanently shrink the addressable market or force repricing.
Uneven Cash ConversionReported profitability is not fully converting to cash, suggesting earnings include noncash or timing items. Weak cash conversion limits self-funded investment, increases reliance on liquidity management, and raises risk that future profits may not sustain operations without stronger OCF.
Sanuwave Health News
SNWV FAQ
What was Sanuwave Health’s price range in the past 12 months?
Sanuwave Health lowest stock price was $15.36 and its highest was $46.59 in the past 12 months.
What is Sanuwave Health’s market cap?
Sanuwave Health’s market cap is $133.81M.
When is Sanuwave Health’s upcoming earnings report date?
Sanuwave Health’s upcoming earnings report date is May 13, 2026 which is in 2 days.
How were Sanuwave Health’s earnings last quarter?
Sanuwave Health released its earnings results on Mar 27, 2026. The company reported $0.9 earnings per share for the quarter, beating the consensus estimate of $0.17 by $0.73.
Is Sanuwave Health overvalued?
According to Wall Street analysts Sanuwave Health’s price is currently Undervalued.
Does Sanuwave Health pay dividends?
Sanuwave Health does not currently pay dividends.
What is Sanuwave Health’s EPS estimate?
Sanuwave Health’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sanuwave Health have?
Sanuwave Health has 8,594,209 shares outstanding.
What happened to Sanuwave Health’s price movement after its last earnings report?
Sanuwave Health reported an EPS of $0.9 in its last earnings report, beating expectations of $0.17. Following the earnings report the stock price went down -1.273%.
Which hedge fund is a major shareholder of Sanuwave Health?
Currently, no hedge funds are holding shares in SNWV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sanuwave Health Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$51.00 (62.94% Upside)
$51.00 (62.94% Upside)
Blogger Sentiment
Bullish
SNWV Sentiment 70%
Sector Average 72%
Sector Average 72%
Insider Transactions
Sold Shares
Worth $2.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
32.00%
12-Months-Change
Fundamentals
Return on Equity
-141.56%
Trailing 12-Months
Asset Growth
23.98%
Trailing 12-Months
Company Description
Sanuwave Health
SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.
SNWV Company Deck
SNWV Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a mix of strong financial performance and clear operational momentum against meaningful industry headwinds. Highlights include record Q4 revenue ($13.4M, +30% YoY), strong full-year revenue growth (+35%) and an 89% increase in full-year adjusted EBITDA, a record number of UltraMIST system placements (624 units, +67% YoY) and improved liquidity (cash $12M). Offsetting these positives are significant external challenges driven by CMS reimbursement changes and aggressive audits that have pressured some customers (leading to 168 discontinued systems), a sales-tax restatement that added roughly $1.6M of G&A expense in 2025 (and similar prior-year impacts), inventory write-offs related to sunsetting product lines, elevated operating expenses, and near-term guidance that is modest (Q1 up 3%–10% YoY) while the company executes a channel shift to resellers and works through manufacturing qualification timing. Management communicated a clear strategy to capitalize on the market disruption (select reseller partnerships, reseller wholesale placements, focus on active systems and new 'baby elephant' customers) and expects improvement through 2026, but uncertainty remains in the near term.View all SNWV earnings summariesSNWV Stock 12 Month Forecast
Average Price Target
$51.00
▲(62.94% Upside)
Technical Analysis
Cerus
―
Senseonics Holdings
―
Tactile Systems Technology
―
Viemed Healthcare
―
Brainsway
―
Ownership Overview
26.11% Insiders
7.40% Mutual Funds
0.53% Other Institutional Investors
58.14% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---